Brian Rini, Audrey Goddard, Dejan Knezevic, Tara Maddala, Ming Zhou, Hakan Aydin, Steven Campbell, Paul Elson, Serge Koscielny, Margarita Lopatin, Christer Svedman, Jean-Francois Martini, J Andrew Williams, Virginie Verkarre, Camelia Radulescu, Yann Neuzillet, Isabelle Hemmerlé, Marc Olivier Timsit, Athanasios C Tsiatis, Michael Bonham, Thierry Lebret, Arnaud Mejean, Bernard Escudier
BACKGROUND: The likelihood of tumour recurrence after nephrectomy in localised clear cell renal cell carcinoma is well characterised by clinical and pathological parameters. However, these assessments can be improved and personalised by the addition of molecular characteristics of each patient's tumour. We aimed to develop and validate a prognostic multigene signature to improve prediction of recurrence risk in clear cell renal cell carcinoma. METHODS: In the development stage, we investigated the association between expression of 732 genes, measured by reverse-transcription PCR, and clinical outcome in 942 patients with stage I-III clear cell renal cell carcinoma who had undergone a nephrectomy at the Cleveland Clinic (OH, USA)...
June 2015: Lancet Oncology